Over at Forbes' The Science Business blog, Matthew Herper reports on Life Technologies' $100 million investment in synthetic biology — including its recent acquisition of a majority stake in Geneart, and an equity investment
Over at Forbes' The Science Business blog, Matthew Herper reports on Life Technologies' $100 million investment in synthetic biology — including its recent acquisition of a majority stake in Geneart, and an equity investment
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.